Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

Why do I think Brilacidin is a good fit for Basilea objectives? This is a easy question but of course you already know the answer.

*Anti-infectives, specifically antifungals and antibiotics, is the key focus of Basilea’s strategy. We have successfully brought two anti-infective drugs to the market: the antifungal Cresemba (isavuconazole) and the antibiotic Zevtera (ceftobiprole).
Oncology was the second area of Basilea’s research and development activities. In February 2022, Basilea announced to focus on anti-infectives and separate its activities in oncology through transactions with partners specialized in oncology.*
https://www.basilea.com/what-we-do

*A key focus for growing shareholder value will be the in-licensing or acquisition of new anti-infective assets in FY23, as Cresemba’s patents are expected to carry through in major markets to 2027. We believe Basilea has had a strong start to FY23 and anticipate management will continue to consider and potentially negotiate licensing deals.*
https://www.edisongroup.com/research/strong-execution-resulting-in-operating-profitability/31896/

And Brilacidin is an excellent anti-infective and anti-fungal that is looking for a partner. Also anti-virus.
*“Brilacidin is now among our best options to fight antimicrobial resistant strains of bacterial infections, one of the scariest global threats,” explained Vincenzo Carnevale, professor of research at CST’s Institute for Computational Molecular Science (ICMS). He noted that the last truly novel class of antimicrobial molecules—not an optimization of preexisting molecules—was approved by the U.S. Food and Drug Administration in 1987.*
https://news.temple.edu/news/2021-12-14/michael-l-klein-wins-prestigious-john-scott-award
https://www.google.com/search?client=firefox-b-1-d&q=google+scholar+brilacidin